In this study, aiming to clarify molecular features of responders in patients of HER2 mutant advanced NSCLC treated with pyrotinib, we collected the ctDNA and performed the biomarker analysis from the pooled analysis of our two previous phase II trials [7, 8]. Here, ERBB2 is linked to non-small cell lung carcinoma.